25.09.22 | Vollzeit | Winterthur | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Biel/Bienne | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Lausanne | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Zürich | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Luzern | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Genève | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Lugano | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | St. Gallen | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Basel (Basel-Stadt) | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehen25.09.22 | Vollzeit | Bern | Roche Glycart AGOf new biotherapeutics, both by computational protein engineering and by the design of in-vitro display libraries using information generated by Next Generation Sequencing and Artificial Intelligence approaches., the origin of drugs like Gazyva, Glofitamab and pREDâs T cell bispecific, costimulatory
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Computational Engineering in der Schweiz kostenlos abonnieren.
 | CV Lebenslauf Upload + WeiterleitungSchnelle One-Click-Bewerbung für ausgewählte Jobinserate durch CV Upload und Weiterleitung (Anmelden). |